ALK and non-small cell lung carcinoma: Brigatinib was superior to crizotinib and ceritinib in PFS and ORR and had an efficacy and safety profile comparable to other 2nd-generation ALK inhibitors in first-line treatments for patients with ALK-positive NSCLC.